Propofol Versus the Use of Dexmedetomidine as a Sedative Agent for Colonosopy

Randomised Study Comparing the Use of Propofol Versus the Use of Dexmedetomidine as a Sedative Agent for Patients Presented for Lower Gastrointestinal Endoscopy

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03466632

Enrollment

100

Registered

2018-03-15

Start date

2016-04-01

Completion date

2020-04-01

Last updated

2018-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colonic Diseases

Brief summary

Dexmedetomidine as a Sedative Agent for Patients Presented for Lower Gastrointestinal Endoscopy

Detailed description

Propofol Versus the Use of Dexmedetomidine as a Sedative Agent for Patients Presented for Lower Gastrointestinal Endoscopy

Interventions

DRUGPropofol

propofol 1.5 mg/kg slow intravenously, followed by maintenance dose of 0.5 mg/kg/h throughout the procedure.

DRUGDexmedetomidine

dexmedetomidine 1 ug/kg over 10 minutes as a bolus dose followed by continuous infusion at a dose of 0.5 ug/kg/h as maintenance dose throughout the procedure

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender

ALL

Age

25 Years to 45 Years

Healthy volunteers

Inclusion criteria

* aged 25-45 years, * ASA class I or II, * who are scheduled for elective outpatient colonoscopy

Exclusion criteria

* refused to give informed consent * if they had known hypersensitivity to the used drugs * patients with morbidly obese patients * patients with increased risk for airway obstruction as obstructive sleep apnea, * Liver diseases

Design outcomes

Primary

Measure	Time frame	Description
Number of patients with adequate sedation	6 months	the number of patients adequately sedated

Countries

Egypt

Contacts

Primary ContactSherief Abd-Elsalam, MD

sheriefabdelsalam@yahoo.com00201095159522

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026